Hemostemix Inc. reports developments tied to its autologous blood-based stem cell therapy platform, including VesCell™ (ACP-01), a patient-derived angiogenic cell therapy associated with ischemic and vascular-related conditions. Company news commonly covers clinical-study history, published results, FDA interactions, physician education, and commercialization activity in markets such as Florida, Canada, and The Bahamas.
Recurring updates also include private placements and other capital actions, leadership and scientific-advisory appointments, shareholder and governance matters, and regulatory planning for ACP-01 across indications including peripheral arterial disease, chronic limb threatening ischemia, angina, cardiomyopathies, congestive heart failure, and vascular dementia.
Hemostemix announced a strategic partnership with CytoImmune Therapeutics to re-establish ACP-01 production at CytoImmune's facility in Puerto Rico. The company secured $1,800,000 in financing commitments through a private placement at $0.05 per unit. CytoImmune will subscribe for $1,370,000 worth of these units. The partnership aims to scale production of ACP-01, a treatment for chronic limb-threatening ischemia (CLTI), potentially reaching sales of $2 million per month by 2025. Hemostemix's phase II clinical trial showed promising results, with 83% of patients experiencing ulcer healing and pain cessation. The proceeds of the financing will be used for initial batch processing and working capital.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.